Wales sets out more on IT supplier selection for GMS Framework Contract

Wales sets out more on IT supplier selection for GMS Framework Contract

February 21 2018 Public Health Wales has published further information about the tendering...

Consultation opens on MoU on data sharing between NHS Digital and Home Office

Consultation opens on MoU on data sharing between NHS Digital and Home Office

February 19 2018 Public Health England is seeking views on the impact of data-sharing...

NHS to distribute KardiaMobile AF diagnosis device

NHS to distribute KardiaMobile AF diagnosis device

February 15 2018 A device the size of a credit card that can be used to diagnose atrial...

NHS Wales opts for Vision and Microtest as preferred GP IT software providers

NHS Wales opts for Vision and Microtest as preferred GP IT software providers

February 1 2018 NHS Wales Informatics Service appears to have dropped EMIS Health as a preferred...

NHS Digital issues guidance on use of off-shore and cloud computing for NHS data

NHS Digital issues guidance on use of off-shore and cloud computing for NHS data

January 23 2018 Healthcare providers wanting to use cloud computing or off-shore storage for...

  • Wales sets out more on IT supplier selection for GMS Framework Contract

    Wales sets out more on IT supplier selection for GMS Framework Contract

    Wednesday, 21 February 2018 15:57
  • Consultation opens on MoU on data sharing between NHS Digital and Home Office

    Consultation opens on MoU on data sharing between NHS Digital and Home Office

    Monday, 19 February 2018 11:03
  • NHS to distribute KardiaMobile AF diagnosis device

    NHS to distribute KardiaMobile AF diagnosis device

    Thursday, 15 February 2018 16:07
  • NHS Wales opts for Vision and Microtest as preferred GP IT software providers

    NHS Wales opts for Vision and Microtest as preferred GP IT software providers

    Thursday, 01 February 2018 11:20
  • NHS Digital issues guidance on use of off-shore and cloud computing for NHS data

    NHS Digital issues guidance on use of off-shore and cloud computing for NHS data

    Tuesday, 23 January 2018 12:24

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

February 23 2018 Health Education England has set out educational content expectations for nursing associates who administer medicines to patients.
February 20 2018 New British Thoracic Society guidelines on pleural mesothelioma include some key recommendations for primary care. The BTS guideline give recommendations and good practice points...